CONMED Corp 8-K

What Happened

• CONMED Corporation filed an 8‑K on May 20, 2026 reporting that its Board increased to nine directors and appointed Celine Martin and Jeff Mirviss as independent, non‑employee directors effective July 1, 2026. Each will serve until the 2027 annual meeting.
• On May 19, 2026 the Board also appointed Kimberly Lockwood as Interim Corporate Controller and Interim Principal Accounting Officer, effective June 1, 2026, and approved a new form of restricted stock unit agreement for non‑employee directors under the 2025 Long‑Term Incentive Plan.
• The Board adopted amended and restated by‑laws on May 19, 2026 (effective immediately) updating advance notice rules and director nomination procedures. CONMED reported final voting results from its May 18, 2026 annual meeting.

Key Details

• New directors: Celine Martin (former J&J MedTech Group Chairman) and Jeff Mirviss (former Boston Scientific executive); both deemed NYSE and SEC independent and will receive prorated non‑employee director compensation.
• Interim accounting officer: Kimberly Lockwood (age 49), CPA, Senior Director, Financial Reporting & Controls since Feb 2025; effective June 1, 2026.
• Bylaw changes: advance notice window for 2027 meeting set to Jan 18–Feb 17, 2027 (i.e., 90–120 days before the first anniversary of the prior year’s meeting); director candidates must make themselves available for Board interviews; other ministerial updates to reflect Delaware law and market practice.
• Annual meeting votes (May 18, 2026): seven directors elected (e.g., Patrick Beyer received 27,649,816 votes for); advisory "say‑on‑pay" approved (26,230,404 for; 1,742,683 against); PricewaterhouseCoopers ratified as auditor for fiscal 2026 (27,295,501 for; 1,636,906 against).

Why It Matters

• Board and governance: Adding two senior medtech executives strengthens CONMED’s board expertise in cardiovascular, peripheral interventions and minimally invasive surgery—relevant for strategy and oversight of product and commercial priorities.
• Governance process: The bylaw amendments tighten nominee notice windows and require director availability for interviews, which affect how shareholders can nominate directors and engage with the company.
• Financial reporting continuity: Appointment of an interim principal accounting officer ensures leadership coverage for financial reporting and controls ahead of any permanent appointment.
• Voting outcomes: Re‑election of directors, approval of executive compensation, and auditor ratification reflect shareholder support for current governance and financial reporting arrangements.